

# David R Matthews

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1930030/david-r-matthews-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

4,342

citations

8

h-index

9

g-index

9

ext. papers

5,510

ext. citations

13.2

avg, IF

5.44

L-index

#	Paper	IF	Citations
9	Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 644-657	59.2	3789
8	Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). <i>Circulation</i> , <b>2018</b> , 137, 323-334	16.7	284
7	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 889-897	6.7	114
6	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 454-466	6.7	57
5	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39
4	Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 335-345	6.7	27
3	Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 188-193	6.7	20
2	Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 530-539	6.7	10
1	Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2199-2203	6.7	2